Following the successful completion of a Phase I/II trial at the Hadassah Medical Center in Jerusalem, Israel, BrainStorm Cell Therapeutics is on track to launch a Phase IIa multi-center ALS trial in the United States (US). BrainStorm just announced that they are completing the final step necessary to submit an Investigational New Drug (IND) application to the Food and Drug Administration (FDA) for approval. This step, involving transfer of intellectual property rights for BrainStorm’s NurOwn™ technology to Dana Farber Cancer Institute (DFCI), is an important milestone, as The Connell and O’Reilly Cell Manipulation Core Facility at DFCI will provide NurOwn to the University of Massachusetts and Massachusetts General Hospital trial sites. The third trial site, the Mayo Clinic, will produce its own supply of NurOwn. Head to BrainStorm’s site to read more.
Click here to read more.Share this: